27 June 2005 00:01 [Source: ICB Americas]
Pfizer has brought on-stream a new facility in Loughbeg, Ireland, dedicated to the production of torcetrapib, a compound being studied in combination with the cholesterol-lowering drug Lipitor (atorvastatin).
The company invested $90 million to expand the Loughbeg facility, which will employ 40 people once fully operational. The plant will use spray-dried dispersion, a new dosage form technology developed in conjunction with Bend Research, to formulate the torcetrapib/atorvastatin combination used in the clinical development program.
The combination drug represents a new strategy in the treatment of cardiovascular diseases: while traditional statins like Lipitor act to lower LDL, or “bad” cholesterol, torcetrapib works to raise levels of HDL, or “good” cholesterol.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.